Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.32 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.31 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13503182 | 0.92 | DNM1 (0.42) | CA12CA1CA9CA2PLA2G1B | |
| SCHEMBL20142568 | 0.90 | DNM1 (0.46) | CA12CA1CA9CA2PLA2G1B | |
| SCHEMBL20142667 | 0.90 | DNM1 (0.46) | CA12CA1CA9CA2PLA2G1B | |
| SCHEMBL20142537 | 0.90 | DNM1 (0.46) | CA12CA1CA9CA2PLA2G1B | |
| SCHEMBL20142540 | 0.90 | DNM1 (0.46) | CA12CA1CA9CA2PLA2G1B | |
| SCHEMBL11257179 | 0.90 | DNM1 (0.46) | CA12CA1CA9CA2PLA2G1B | |
| SCHEMBL20142252 | 0.90 | DNM1 (0.46) | CA12CA1CA9CA2PLA2G1B | |
| SCHEMBL20142321 | 0.90 | DNM1 (0.46) | CA12CA1CA9CA2PLA2G1B | |
| SCHEMBL9043631 | 0.90 | DNM1 (0.46) | CA12CA1CA9CA2PLA2G1B | |
| SCHEMBL14731786 | 0.90 | DNM1 (0.46) | CA12CA1CA9CA2PLA2G1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11077197-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-08-03 | — | — | US | claimed |
| CN-105709229-B | Novel lipids and compositions for delivery of therapeutic agents | 阿布特斯生物制药公司 | 2020-07-28 | — | — | CN | claimed |
| US-20180092971-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-04-05 | — | — | US | claimed |
| EP-3284482-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | Arbutus Biopharma Corporation (CA) | 2018-02-21 | — | — | EP | claimed |
| US-9707292-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2017-07-18 | — | — | US | claimed |
| US-9186325-B2 | Lipids and compositions for the delivery of therapeutics | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2015-11-17 | — | — | US | claimed |
| US-12042541-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-23 | — | — | US | disclosed |
| EP-3757090-B1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORP (CA) | 2024-06-12 | — | — | EP | disclosed |
| US-11911483-B2 | Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240042039-A1 | LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-02-08 | — | — | US | disclosed |
| WO-2024020034-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230381319-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (US) | 2023-11-30 | — | — | US | disclosed |
| US-5871572-A | COLORANT, WATER, A WATER-SOLUBLE ORGANIC SOLVENT, AND PECTIC ACID | SEIKO EPSON CORPORATION (JP) | 1999-02-16 | — | — | US | disclosed |
| EP-0838508-A2 | Aqueous ink composition for use in an ink-jet printer | SEIKO EPSON CORPORATION (JP) | 1998-04-29 | — | — | EP | disclosed |
| US-4037017-A | CATIONIC POLYAMINE | HERCULES INCORPORATED (US) | 1977-07-19 | — | — | US | disclosed |
| US-3972911-A | PROPHYLAXIS | THE UPJOHN COMPANY (US) | 1976-08-03 | — | — | US | disclosed |
| US-3966684-A | RETENTION AIDS FOR PAPER FILLERS | HERCULES INCORPORATED (US) | 1976-06-29 | — | — | US | disclosed |
| US-3966694-A | RETENTION AIDS FOR PAPER FILLERS | HERCULES INCORPORATED (US) | 1976-06-29 | — | — | US | disclosed |
| US-3951921-A | PAPER FILLERS | HERCULES INCORPORATED (US) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11911483-B2 | Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making | PAICS, UGT1A1, CYP7A1 | CA12 207/4885CA1 254/4885CA9 354/4885 |
| US-20230381319-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | SGMS2, SGMS1, PHOSPHO1 | CA12 4129/4885CA1 4737/4885CA9 4134/4885 |
| US-12042541-B2 | Lipids and compositions for the delivery of therapeutics | PHOSPHO1, MBOAT1, SGMS1 | CA12 3757/4885CA1 4606/4885CA9 4185/4885 |
| US-20240042039-A1 | LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | PHOSPHO1, MBOAT1, SGMS1 | CA12 3757/4885CA1 4606/4885CA9 4185/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | CA12 1095/4885CA1 1094/4885CA9 1153/4885 |
| US-11077197-B2 | Lipids and compositions for the delivery of therapeutics | SGMS2, APOB, MBOAT1 | CA12 2383/4885CA1 4166/4885CA9 3132/4885 |
| US-20180092971-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | PHOSPHO1, SGMS2, MBOAT1 | CA12 2354/4885CA1 4286/4885CA9 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.